Aflibercept 8 mg positive pivotal results in diabetic macular edema and wet age-related macular degeneration presented at aao

Photon and pulsar data presentations demonstrate aflibercept 8 mg led to sustained improvements in vision and anatomic measures of retinal fluid across the 48-week treatment period in both 12- and 16-week dosing regimens tarrytown, n.y. , sept. 30, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to eylea® (aflibercept) injection, in patients with diabetic macular edema (dme) and wet age-related macular degeneration (wamd).
REGN Ratings Summary
REGN Quant Ranking